SBIR/STTR Research Award
Rapid SARS-CoV-2 Spike Protein Neutralizing Antibody Tests for Evaluating COVID Vaccine-Generated Immunity
Award amount
$242,132Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Centers for Disease Control and Prevention
- Recipient company
- DL ADV-TECH, LLC
- Proposal award date
- 2021-09-30
- Contract end date
- 2022-03-31
- UEI
- KUFGHGVAR634
- Solicitation number
- PA20-260
- Topic code
- NCIRD
Research abstract
ABSTRACT: In this Phase I project, we focus on demonstration of a reliable SARS-CoV-2 S-protein neutralizing antibodies (nAbs) testing device for rapid quantification of nAbs concentrations. The major significance of the proposed approach is the ability to accurately, quickly and massively quantify SARS-CoV-2 S-protein nAbs by leveraging our advanced mesoporous nanoflowers (MNFs) signal amplification technique (patent pending) and smartphone-based readout technique. The proposed technique will offer a powerful tool to accurately and closely monitor SARS-CoV-2 S-protein nAbs levels at a large population scale and provide confidence to individuals and clinicians to fight this pandemic.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Multiplexed biosensor for personal wildfire exposure assessment
- Single-Atom Nanozyme Enhanced Handheld Biosensor for Measurement of Pesticide Exposures
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
- Development of Antigen-based Vertical Flow Assay for the Rapid Detection of SARS-CoV-2, Influenza A/B, and RSV
- Rapid mass production of human influenza vaccine in insects using genome editing
- A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines
- Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus
Research funding history
3 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $647,998. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services